Showing 4621-4630 of 20465 results for "".
- Brepocitinib Phase 3 Trial Findings in Dermatomyositishttps://reachmd.com/news/brepocitinib-dermatomyositis-trial/2487352/Key Takeaways Brepocitinib 30 mg was associated with a higher week-52 Total Improvement Score than placebo in adults with dermatomyositis. The 30-mg dose was also superior across all nine key secondary end points, with improvement observed by week 4.</
- Phase 3 Bepirovirsen Trial Shows HBsAg Loss In Chronic Hepatitis Bhttps://reachmd.com/news/bepirovirsen-hbsag-chronic-hepatitis-b/2487336/Key Takeaways Week-72 functional cure occurred more often with bepirovirsen than with placebo in both trials. Response rates were higher among participants with lower baseline HBsAg concentrations. Adverse events, including grade 3 or higher e
- TDN Grading in Aneurysmal Subarachnoid Hemorrhagehttps://reachmd.com/news/tdn-aneurysmal-subarachnoid-hemorrhage/2487350/Key Takeaways Investigators retrospectively applied TDN to charted adverse events in 355 treated patients, and higher grades were associated with longer hospitalization and poorer recovery. Higher TDN grades were linked to lower Glasgow Outcome Scale s
- Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Cancerhttps://reachmd.com/news/daraxonrasib-metastatic-pancreatic-cancer/2487354/Key Takeaways Daraxonrasib was associated with longer overall survival and progression-free survival than investigator's choice chemotherapy in the prespecified RAS G12 population. Benefit was also reported in the overall population, and 91.8% of enrol
- FRONTIER3: Tozorakimab Shows Signal in Early-Onset Asthmahttps://reachmd.com/news/tozorakimab--frontier3-asthma/2487324/Key Takeaways In the intent-to-treat population, the week 16 primary endpoint was not statistically significant versus placebo. Patients with at least 2 prior exacerbations showed greater improvement in clinic pre-BD FEV1, especially with 600 mg.
- Buntanetap in Mild-to-Moderate Alzheimer’s: Phase 2/3 Study Findingshttps://reachmd.com/news/buntanetap-mild-moderate-alzheimers/2487325/Key Takeaways In the intent-to-treat population, primary endpoints changed similarly in pooled buntanetap and placebo groups; however, post-hoc analyses showed 38% of participants lacked amyloid burden. Buntanetap was well tolerated, with no serious tr
- Study Supports PLLA-SCA for Décolletage Rejuvenationhttps://reachmd.com/news/study-supports-plla-sca-for-decolletage-rejuvenation/2487331/Poly-L-lactic acid for injectable suspension (PLLA-SCA; Sculptra, Galderma) was effective and well tolerated for correction of moderate to severe décolletage wrinkles using either 8-mL or 17-mL reconstitution volumes, according to findings from a 9-month, open-label study published in the Jou
- Genital Psoriasis Consensus Offers Age-Specific Roadmap for Clinical Carehttps://reachmd.com/news/genital-psoriasis-consensus-offers-age-specific-roadmap-for-clinical-care/2487330/A new expert consensus manuscript in the American Journal of Clinical Dermatology offered recommendations aimed at improving the diagnosis and management of genital psoriasis, according to a press release from Arcutis. The publication represents the second manuscript, Arcutis said
- Headache on the Hill 2026 Recap: Advocacy, Policy Priorities, And Accesshttps://reachmd.com/news/headache-on-the-hill-2026-recap-advocacy-policy-priorities-and-access/2487314/Key Takeaways The event brought together 282 advocates from 47 states, including patients, caregivers, researchers, clinicians, and about 20 youth advocates. The HEADACHE Act, the Safe Step Act, and the CONNECT for Health Act were the highlighted feder
- Roche Details ADA 2026 Obesity Portfolio Presentationshttps://reachmd.com/news/roche-details-ada-2026-obesity-portfolio-presentations/2487320/Key Takeaways Roche is previewing late-breaking Phase II data at ADA 2026 for enicepatide from CT388-103 and for petrelintide from ZUPREME-1. Roche says both assets are moving into Phase III development, and a Phase II multi-arm fixed-dose combination